Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function

Huntington's disease (HD) is a progressive, fatal neurological condition caused by an expansion of CAG (glutamine) repeats in the coding region of the Huntington gene. To date, there is no cure but great strides have been made to understand pathophysiological mechanisms. In particular, genetic animal models of HD have been instrumental in elucidating the progression of behavioral and physiological alterations, which had not been possible using classic neurotoxin models. Our groups have pioneered the use of transgenic HD mice to examine the excitotoxicity hypothesis of striatal neuronal dysfunction and degeneration, as well as alterations in excitation and inhibition in striatum and cerebral cortex. In this review, we focus on synaptic and receptor alterations of striatal medium-sized spiny (MSNs) and cortical pyramidal neurons in genetic HD mouse models. We demonstrate a complex series of alterations that are region-specific and time-dependent. In particular, many changes are bidirectional depending on the degree of disease progression, that is, early vs. late, and also on the region examined. Early synaptic dysfunction is manifested by dysregulated glutamate release in striatum followed by progressive disconnection between cortex and striatum. The differential effects of altered glutamate release on MSNs originating the direct and indirect pathways is also elucidated, with the unexpected finding that cells of the direct striatal pathway are involved early in the course of the disease. In addition, we review evidence for early N-methyl-D-aspartate receptor (NMDAR) dysfunction leading to enhanced sensitivity of extrasynaptic receptors and a critical role of GluN2B subunits. Some of the alterations in late HD could be compensatory mechanisms designed to cope with early synaptic and receptor dysfunctions. The main findings indicate that HD treatments need to be designed according to the stage of disease progression and should consider regional differences.

[1]  G. Rebec,et al.  Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: Variations with behavioral state and repeated ascorbate treatment , 2006, Neuroscience.

[2]  S. Lipton Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.

[3]  P. Greengard,et al.  Regulation of NMDA receptor trafficking by amyloid-β , 2005, Nature Neuroscience.

[4]  L. Raymond,et al.  Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease , 2004, Molecular and Cellular Neuroscience.

[5]  C. Cepeda,et al.  Differential sensitivity of medium‐ and large‐sized striatal neurons to NMDA but not kainate receptor activation in the rat , 2001, The European journal of neuroscience.

[6]  Y. Smith,et al.  The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat , 1990, Brain Research.

[7]  Nicola Biagio Mercuri,et al.  Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine , 2009, Movement disorders : official journal of the Movement Disorder Society.

[8]  D. Sibley,et al.  Striatal neurochemical changes in transgenic models of Huntington's disease , 2002, Journal of neuroscience research.

[9]  J. Bolam,et al.  Synaptic organisation of the basal ganglia , 2000, Journal of anatomy.

[10]  I. Divac,et al.  Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain , 1981, Neuroscience.

[11]  Bruce Fischl,et al.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.

[12]  He Li,et al.  Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. , 2003, Human molecular genetics.

[13]  C. Cepeda,et al.  Dopamine and Glutamate in Huntington's Disease: A Balancing Act , 2010, CNS neuroscience & therapeutics.

[14]  Jacki Y. Brown,et al.  Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. , 2006, Human molecular genetics.

[15]  J. Coyle,et al.  In situ injection of kainic acid: A new method for selectively lesioning neuronal cell bodies while sparing axons of passage , 1978, The Journal of comparative neurology.

[16]  L. Raymond,et al.  Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease , 2010, Trends in Neurosciences.

[17]  S. Folstein,et al.  Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.

[18]  Hilmar Bading,et al.  Nuclear Calcium Signaling Controls Expression of a Large Gene Pool: Identification of a Gene Program for Acquired Neuroprotection Induced by Synaptic Activity , 2009, PLoS genetics.

[19]  C. Gerfen The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. , 1992, Annual review of neuroscience.

[20]  Carlos Cepeda,et al.  Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect , 2004, Trends in Neurosciences.

[21]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[22]  K. Davies,et al.  Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices , 2009, Neuroscience.

[23]  Anatol C. Kreitzer,et al.  Distinct Roles of GABAergic Interneurons in the Regulation of Striatal Output Pathways , 2010, The Journal of Neuroscience.

[24]  D. Bredt,et al.  Ion Channel Clustering by Membrane-associated Guanylate Kinases , 2000, The Journal of Biological Chemistry.

[25]  Michael R. Hayden,et al.  Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease , 2008, Neurobiology of Disease.

[26]  E Maran,et al.  Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntington's Disease , 1990, Journal of neuropathology and experimental neurology.

[27]  E. Stern,et al.  Functional Changes in Neocortical Activity in Huntington's Disease Model Mice: An in vivo Intracellular Study , 2011, Front. Syst. Neurosci..

[28]  G. Uhl,et al.  Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[30]  J. Lucas,et al.  Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity , 2009, Neurobiology of Disease.

[31]  C. Gerfen,et al.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.

[32]  S. Hersch,et al.  HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. , 2002, Human molecular genetics.

[33]  Yvette E. Fisher,et al.  Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids , 2010, The European journal of neuroscience.

[34]  M. Chesselet,et al.  Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice , 2002, The Journal of Neuroscience.

[35]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Penney,et al.  Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.

[37]  M. Ehlers Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system , 2003, Nature neuroscience.

[38]  J. Olson,et al.  Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.

[39]  Françoise Condé,et al.  Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.

[40]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[41]  G. Egan,et al.  Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease , 2008, Brain Research Reviews.

[42]  J. Coyle,et al.  Striatal lesions with kainic acid: neurochemical characteristics , 1977, Brain Research.

[43]  P. Greengard,et al.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.

[45]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[46]  J. Coyle,et al.  Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.

[47]  P. Ghazal,et al.  Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses , 2008, Nature Neuroscience.

[48]  C. Cepeda,et al.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease , 2007, Molecular Neurodegeneration.

[49]  J. Penney,et al.  Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.

[50]  Thomas Walther,et al.  Transgenic rat model of Huntington's disease. , 2003, Human molecular genetics.

[51]  R. Duncan,et al.  Specific Targeting of Pro-Death NMDA Receptor Signals with Differing Reliance on the NR2B PDZ Ligand , 2008, The Journal of Neuroscience.

[52]  Max Kleiman-Weiner,et al.  Differential electrophysiological properties of dopamine D1 and D2 receptor‐containing striatal medium‐sized spiny neurons , 2008, The European journal of neuroscience.

[53]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[54]  A. Morton,et al.  Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation , 2006, Brain Research Bulletin.

[55]  Wolfgang Eisenmenger,et al.  Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington’s disease , 2009, Acta Neuropathologica.

[56]  D. Surmeier,et al.  Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study. , 1996, Molecular pharmacology.

[57]  K. Murphy,et al.  Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease , 2007, Brain Research Bulletin.

[58]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[59]  B. Gloss,et al.  Drd1a-tdTomato BAC Transgenic Mice for Simultaneous Visualization of Medium Spiny Neurons in the Direct and Indirect Pathways of the Basal Ganglia , 2008, The Journal of Neuroscience.

[60]  Yvette E. Fisher,et al.  SYSTEMS NEUROSCIENCE ORIGINAL RESEARCH ARTICLE , 2011 .

[61]  Alexander Z. Harris,et al.  Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices , 2007, The Journal of physiology.

[62]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[63]  G. Landwehrmeyer,et al.  NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[64]  A M Graybiel,et al.  Cortically Driven Immediate-Early Gene Expression Reflects Modular Influence of Sensorimotor Cortex on Identified Striatal Neurons in the Squirrel Monkey , 1997, The Journal of Neuroscience.

[65]  M. Chesselet,et al.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice , 2008, Neuroscience.

[66]  M. Hayden,et al.  Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity , 2004, Journal of Biological Chemistry.

[67]  L. Raymond,et al.  Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load , 2007, The Journal of physiology.

[68]  R. Petralia,et al.  Organization of NMDA receptors at extrasynaptic locations , 2010, Neuroscience.

[69]  D. Purpura,et al.  Recruiting Extrasynaptic NMDA Receptors Augments Synaptic Signaling , 2007 .

[70]  S. Lipton,et al.  Memantine Preferentially Blocks Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses , 2010, The Journal of Neuroscience.

[71]  Marian DiFiglia,et al.  Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.

[72]  David S Tuch,et al.  Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures , 2006, Movement disorders : official journal of the Movement Disorder Society.

[73]  D. James Surmeier,et al.  Re-emergence of striatal cholinergic interneurons in movement disorders , 2007, Trends in Neurosciences.

[74]  Francois Gonon,et al.  Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism , 2008, The European journal of neuroscience.

[75]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[76]  Carlos Cepeda,et al.  Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF , 2004, Journal of neuroscience research.

[77]  Carlos Cepeda,et al.  Dissecting the Contribution of Individual Receptor Subunits to the Enhancement of N-methyl-d-Aspartate Currents by Dopamine D1 Receptor Activation in Striatum , 2011, Front. Syst. Neurosci..

[78]  Charles J. Wilson,et al.  Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons , 2008, Brain Research Reviews.

[79]  Robert C. Malenka,et al.  Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models , 2007, Nature.

[80]  Y. Smith,et al.  The thalamostriatal system: a highly specific network of the basal ganglia circuitry , 2004, Trends in Neurosciences.

[81]  J. Kemp,et al.  Developmental Changes in NMDA Receptor Glycine Affinity and Ifenprodil Sensitivity Reveal Three Distinct Populations of NMDA Receptors in Individual Rat Cortical Neurons , 1998, The Journal of Neuroscience.

[82]  P. Brundin,et al.  Maintenance of Susceptibility to Neurodegeneration Following Intrastriatal Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease , 2002, Experimental Neurology.

[83]  D. Riche,et al.  A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon , 1990, Experimental Neurology.

[84]  M. Sheng,et al.  Differential Roles of NR2A- and NR2B-Containing NMDA Receptors in Ras-ERK Signaling and AMPA Receptor Trafficking , 2005, Neuron.

[85]  Carlos Cepeda,et al.  Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease , 2009, The Journal of Neuroscience.

[86]  C. Gerfen The neostriatal mosaic: multiple levels of compartmental organization , 1992, Trends in Neurosciences.

[87]  A. Kriegstein,et al.  Glutamate neurotoxicity in cortical cell culture , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[88]  A. Morton,et al.  Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation , 2000, Journal of neurocytology.

[89]  L. Raymond,et al.  Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice , 2010, Neuron.

[90]  L. Raymond,et al.  P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease , 2012, Neurobiology of Disease.

[91]  Jan Kassubek,et al.  Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study , 2004, Neuroreport.

[92]  C. Hillard,et al.  Differential Regulation of the Endocannabinoids Anandamide and 2-Arachidonylglycerol within the Limbic Forebrain by Dopamine Receptor Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[93]  S. Cull-Candy,et al.  Role of Distinct NMDA Receptor Subtypes at Central Synapses , 2004, Science's STKE.

[94]  Rand Askalan,et al.  Tyrosine Phosphatase STEP Is a Tonic Brake on Induction of Long-Term Potentiation , 2002, Neuron.

[95]  L. Ellerby,et al.  Calpain Activation in Huntington's Disease , 2002, The Journal of Neuroscience.

[96]  Angus C. Nairn,et al.  Synaptic plasticity: one STEP at a time , 2006, Trends in Neurosciences.

[97]  J. Hodges,et al.  Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers , 2001, Psychiatry Research.

[98]  M. Hayden,et al.  Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[99]  Patrik Brundin,et al.  Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.

[100]  D. Surmeier,et al.  Dichotomous Anatomical Properties of Adult Striatal Medium Spiny Neurons , 2008, The Journal of Neuroscience.

[101]  Sheree D. Cherry Calcium channel dysfunction in Huntington's disease , 2009 .

[102]  M. Hayden,et al.  Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease , 2007, Neuroscience.

[103]  P. Mcgeer,et al.  Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.

[104]  Claire-Anne Gutekunst,et al.  Huntingtin-Interacting Protein HIP14 Is a Palmitoyl Transferase Involved in Palmitoylation and Trafficking of Multiple Neuronal Proteins , 2004, Neuron.

[105]  Carlos Cepeda,et al.  Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease , 2010, ASN neuro.

[106]  C. Gerfen,et al.  The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[107]  A. Buisson,et al.  Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[108]  Charles J. Wilson,et al.  GABAergic microcircuits in the neostriatum , 2004, Trends in Neurosciences.

[109]  Elsdon Storey,et al.  Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.

[110]  M. Hayden,et al.  Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. , 2008, Brain : a journal of neurology.

[111]  D. Coulter,et al.  Fyn-mediated Phosphorylation of NR2B Tyr-1336 Controls Calpain-mediated NR2B Cleavage in Neurons and Heterologous Systems* , 2007, Journal of Biological Chemistry.

[112]  J. Penney,et al.  Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity‐akinesia , 1990, Annals of neurology.

[113]  J. Isaac,et al.  Casein Kinase 2 Regulates the NR2 Subunit Composition of Synaptic NMDA Receptors , 2010, Neuron.

[114]  Yu Deng,et al.  Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease , 2009, The Journal of Neuroscience.

[115]  P. Mcgeer,et al.  A glutamatergic corticostriatal path? , 1977, Brain Research.

[116]  H. Steinbusch,et al.  Hyperdopaminergic Status in Experimental Huntington Disease , 2010, Journal of neuropathology and experimental neurology.

[117]  L. Raymond,et al.  Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin , 1999, Journal of neurochemistry.

[118]  E. Cattaneo,et al.  Role of brain-derived neurotrophic factor in Huntington's disease , 2007, Progress in Neurobiology.

[119]  S. T. Kitai,et al.  Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[120]  G. Westbrook,et al.  Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. , 2006, Journal of neurophysiology.

[121]  I. Módy,et al.  Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice , 2005, Neuron.

[122]  A. Laverghetta,et al.  Differential morphology of pyramidal tract‐type and intratelencephalically projecting‐type corticostriatal neurons and their intrastriatal terminals in rats , 2003, The Journal of comparative neurology.

[123]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[124]  D J Brooks,et al.  Microglial activation correlates with severity in Huntington disease , 2006, Neurology.

[125]  D. Rubinsztein,et al.  Huntington's disease: from pathology and genetics to potential therapies. , 2008, The Biochemical journal.

[126]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[127]  R. Nicoll,et al.  Activity-dependent NMDA receptor degradation mediated by retrotranslocation and ubiquitination. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[128]  Carlos Cepeda,et al.  Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.

[129]  K. Roche,et al.  Regulation of NMDA receptors by phosphorylation , 2007, Neuropharmacology.

[130]  H. Tanila,et al.  Orexin loss in Huntington's disease. , 2005, Human molecular genetics.

[131]  A. Graybiel Neurotransmitters and neuromodulators in the basal ganglia , 1990, Trends in Neurosciences.

[132]  H. Bading,et al.  Hypoxic/ischemic conditions induce expression of the putative pro-death gene Clca1 via activation of extrasynaptic N-methyl-d-aspartate receptors , 2009, Neuroscience.

[133]  G. Deuschl,et al.  Deep brain stimulation in Parkinson's disease following fetal nigral transplantation , 2008, Movement disorders : official journal of the Movement Disorder Society.

[134]  J. Penney,et al.  Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis , 1995, Neuroscience.

[135]  H. Parthasarathy,et al.  Local Release of GABAergic Inhibition in the Motor Cortex Induces Immediate-Early Gene Expression in Indirect Pathway Neurons of the Striatum , 1997, The Journal of Neuroscience.

[136]  David H Salat,et al.  Complexity and Heterogeneity: What Drives the Ever‐changing Brain in Huntington's Disease? , 2008, Annals of the New York Academy of Sciences.

[137]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[138]  M. Mayer,et al.  Permeation and block of N‐methyl‐D‐aspartic acid receptor channels by divalent cations in mouse cultured central neurones. , 1987, The Journal of physiology.

[139]  Roger L Albin,et al.  Longitudinal Evaluation of the Hdh (CAG)150 Knock-In Murine Model of Huntington's Disease , 2007, The Journal of Neuroscience.

[140]  E. Bird,et al.  Chemical pathology of Huntington's disease. , 1980, Annual review of pharmacology and toxicology.

[141]  Carlos Cepeda,et al.  Genetic mouse models of Huntington’s disease: focus on electrophysiological mechanisms , 2010, ASN neuro.

[142]  H. Bading,et al.  A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-to-nucleus communication , 2001, Nature Neuroscience.

[143]  L. Raymond,et al.  Altered NMDA Receptor Trafficking in a Yeast Artificial Chromosome Transgenic Mouse Model of Huntington's Disease , 2007, The Journal of Neuroscience.

[144]  R. Nicoll,et al.  PSD-95 involvement in maturation of excitatory synapses. , 2000, Science.

[145]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[146]  J. Penney,et al.  NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.

[147]  Carlos Cepeda,et al.  The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.

[148]  Jing Fan,et al.  Interaction of Postsynaptic Density Protein-95 with NMDA Receptors Influences Excitotoxicity in the Yeast Artificial Chromosome Mouse Model of Huntington's Disease , 2009, The Journal of Neuroscience.

[149]  J. Bibb,et al.  Extrasynaptic NMDA Receptors Couple Preferentially to Excitotoxicity via Calpain-Mediated Cleavage of STEP , 2009, The Journal of Neuroscience.

[150]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[151]  M. Ehrlich,et al.  Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. , 2008, Human molecular genetics.

[152]  A. Mahal,et al.  Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice , 2001, Neurobiology of Disease.

[153]  Stephen B. Dunnett,et al.  Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation , 1999, The Journal of Neuroscience.

[154]  M. MacDonald,et al.  Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. , 2000, Human molecular genetics.

[155]  C. Gerfen,et al.  Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons , 1999, Neuroscience.

[156]  R. Schwarcz,et al.  II: Excitotoxic models for neurodegenerative disorders , 1984 .

[157]  M. Hayden,et al.  Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors , 2006, The Journal of Neuroscience.

[158]  J. Tsien,et al.  In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease , 2009, The Journal of Neuroscience.

[159]  J. Xuereb,et al.  The messenger RNAs for the N-methyl- d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain , 1996, Neuroscience.

[160]  D. Surmeier,et al.  Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons , 1996, The Journal of Neuroscience.

[161]  Jun O. Liu,et al.  Calpain-dependent cleavage of cain/cabin1 activates calcineurin to mediate calcium-triggered cell death , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[162]  M. Bennett,et al.  Postsynaptic Density Protein-95 Regulates NMDA Channel Gating and Surface Expression , 2004, The Journal of Neuroscience.

[163]  Scott H Chandler,et al.  Striatal potassium channel dysfunction in Huntington's disease transgenic mice. , 2005, Journal of neurophysiology.

[164]  Masahiko Watanabe,et al.  Role of the Carboxy-Terminal Region of the GluRε2 Subunit in Synaptic Localization of the NMDA Receptor Channel , 1998, Neuron.

[165]  W. Nauta,et al.  Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry , 1983, Neuroscience.

[166]  G. Johnson,et al.  Mutant Huntingtin Expression Induces Mitochondrial Calcium Handling Defects in Clonal Striatal Cells , 2006, Journal of Biological Chemistry.

[167]  Y. Kawaguchi,et al.  Recurrent Connection Patterns of Corticostriatal Pyramidal Cells in Frontal Cortex , 2006, The Journal of Neuroscience.

[168]  J. Epplen,et al.  Chorea Huntington: A Rare Case with Childhood Onset , 2002, Neuropediatrics.

[169]  L. Raymond,et al.  Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease , 2006, Neurobiology of Disease.

[170]  A E Rosser,et al.  Evidence for specific cognitive deficits in preclinical Huntington's disease. , 1998, Brain : a journal of neurology.

[171]  Shaun S. Sanders,et al.  Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease , 2010, Neurobiology of Disease.

[172]  S. Hersch,et al.  Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice , 2007, The Journal of Neuroscience.

[173]  Yvette E. Fisher,et al.  Differential Electrophysiological Changes in Striatal Output Neurons in Huntington's Disease , 2011, The Journal of Neuroscience.

[174]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[175]  Yen F. Tai,et al.  Imaging microglial activation in Huntington's disease , 2007, Brain Research Bulletin.

[176]  G. Reynolds,et al.  The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease , 2002, Journal of neurochemistry.

[177]  Timothy H Murphy,et al.  Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. , 2004, Journal of neurophysiology.

[178]  D. Bredt,et al.  Lipid- and protein-mediated multimerization of PSD-95: implications for receptor clustering and assembly of synaptic protein networks , 2003, Journal of Cell Science.

[179]  L. Bäckman,et al.  Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. , 2001, Scandinavian journal of psychology.

[180]  Michael R. Hayden,et al.  Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin , 2009, Nature Medicine.

[181]  E. Spokes The neurochemistry of Huntington's chorea , 1981, Trends in Neurosciences.

[182]  D. Sengelaub,et al.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse , 2008, Neuroscience.

[183]  M. Guillermier,et al.  In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects , 2010, Human molecular genetics.

[184]  Neal Sweeney,et al.  Synaptic Strength Regulated by Palmitate Cycling on PSD-95 , 2002, Cell.

[185]  Kai Chang,et al.  The Synaptic Localization of NR2B-Containing NMDA Receptors Is Controlled by Interactions with PDZ Proteins and AP-2 , 2005, Neuron.

[186]  A. Parent,et al.  Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease , 2000, Brain Research Reviews.

[187]  Coyle Jt An animal model for Huntington's disease. , 1979 .

[188]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[189]  L. Cif,et al.  Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. , 2008, Journal of neurosurgery.

[190]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[191]  Scott J Barton,et al.  Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease. , 2008, Journal of neurophysiology.

[192]  G. Bernardi,et al.  Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene , 2001, The European journal of neuroscience.

[193]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[194]  Robert Lipsky,et al.  The excitoprotective effect of N‐methyl‐d‐aspartate receptors is mediated by a brain‐derived neurotrophic factor autocrine loop in cultured hippocampal neurons , 2005, Journal of neurochemistry.

[195]  R. Neumar,et al.  Selective Activation Induced Cleavage of the NR2B Subunit by Calpain , 2003, The Journal of Neuroscience.

[196]  R N Gunn,et al.  Huntington's disease progression. PET and clinical observations. , 1999, Brain : a journal of neurology.

[197]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[198]  Y. Ben-Ari,et al.  Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal‐regulated kinases (ERK) activity in cultured rat hippocampal neurons , 2006, The Journal of physiology.

[199]  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2003 .

[200]  M. Giordano,et al.  The quinolinic acid model of Huntington's disease: Locomotor abnormalities , 1989, Experimental Neurology.

[201]  Jacqueline K. White,et al.  Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion , 1997, Nature Genetics.

[202]  Kemp Jm The site of termination of afferent fibres on the neurones of the caudate nucleus. , 1970 .

[203]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[204]  S. Goto,et al.  An immunohistochemical investigation of the human neostriatum in huntington's disease , 1989, Annals of neurology.

[205]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[206]  Jane S. Paulsen Functional imaging in Huntington's disease , 2009, Experimental Neurology.

[207]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[208]  L. Raymond,et al.  Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease , 2003, Neurobiology of Aging.

[209]  R. Huganir,et al.  Dual Palmitoylation of NR2 Subunits Regulates NMDA Receptor Trafficking , 2009, Neuron.

[210]  R. Porter,et al.  Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum , 1993, Journal of neurochemistry.

[211]  I. Módy,et al.  Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease , 2008, Neuroscience.

[212]  T. Hökfelt,et al.  Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. , 1982, European journal of pharmacology.

[213]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[214]  K. Roche,et al.  Subunit-Specific Regulation of NMDA Receptor Endocytosis , 2004, The Journal of Neuroscience.

[215]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[216]  D. Jane,et al.  Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. , 2000, The Journal of pharmacology and experimental therapeutics.

[217]  A. Morton,et al.  Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation , 1999, The Journal of Neuroscience.

[218]  R. Llinás,et al.  Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[219]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[220]  D. Geschwind,et al.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. , 2011, Human molecular genetics.

[221]  S B Dunnett,et al.  Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.

[222]  L. Bäckman,et al.  Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.

[223]  C. Cepeda,et al.  Alterations in N‐methyl‐D‐aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease , 2005, Journal of neuroscience research.

[224]  N. Déglon,et al.  Mitochondria in Huntington's disease. , 2010, Biochimica et biophysica acta.

[225]  S. Jones,et al.  Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington’s disease , 2007, Neuroscience.

[226]  Roberto Malinow,et al.  Subunit-Specific NMDA Receptor Trafficking to Synapses , 2002, Neuron.

[227]  M. Hayden,et al.  Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-(1,4,5) Triphosphate Receptor Type 1 , 2003, Neuron.

[228]  A. Reiner,et al.  Evidence for Differential Cortical Input to Direct Pathway versus Indirect Pathway Striatal Projection Neurons in Rats , 2004, The Journal of Neuroscience.

[229]  Jiahuai Han,et al.  Distinct Requirements for p38α and c-Jun N-terminal Kinase Stress-activated Protein Kinases in Different Forms of Apoptotic Neuronal Death* , 2004, Journal of Biological Chemistry.

[230]  J. Deniau,et al.  Disinhibition as a basic process in the expression of striatal functions , 1990, Trends in Neurosciences.

[231]  S. W. Davies,et al.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[232]  C. Cepeda,et al.  Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.

[233]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[234]  Jacki Y. Brown,et al.  Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. , 2006, Human molecular genetics.

[235]  Ji-Yeon Shin,et al.  Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.

[236]  D. Oorschot,et al.  Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. , 2010, Brain : a journal of neurology.

[237]  B Fischl,et al.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.

[238]  L. Raymond,et al.  N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease , 2007, Progress in Neurobiology.

[239]  H. D. Rosas,et al.  Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington’s disease , 2004, NeuroRX.

[240]  P S Harper,et al.  Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain. , 1996, Human molecular genetics.

[241]  A. Tobin,et al.  Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.

[242]  D. Lucas,et al.  The toxic effect of sodium L-glutamate on the inner layers of the retina. , 1957, A.M.A. archives of ophthalmology.

[243]  M. Tymianski,et al.  Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. , 2003, Cell calcium.

[244]  Cheng-Wei Lu,et al.  Memantine depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase C in rat cerebral cortex nerve terminals: An NMDA receptor-independent mechanism , 2010, Neurochemistry International.

[245]  M. Salter,et al.  Regulation of NMDA Receptors by Kinases and Phosphatases , 2009 .

[246]  M. Beal,et al.  Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease , 1998, Journal of neurochemistry.

[247]  Joseph B. Martin,et al.  Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease , 1987, Brain Research.

[248]  B. D. de Jong,et al.  Changes in striatal dopamine D2 receptor binding in pre‐clinical Huntington’s disease , 2008, European journal of neurology.

[249]  L. Raymond,et al.  Polyglutamine-Modulated Striatal Calpain Activity in YAC Transgenic Huntington Disease Mouse Model: Impact on NMDA Receptor Function and Toxicity , 2008, The Journal of Neuroscience.

[250]  Philip A. Starr,et al.  Pallidal neuronal discharge in Huntington's disease: Support for selective loss of striatal cells originating the indirect pathway , 2008, Experimental Neurology.

[251]  R. Yasuda,et al.  Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. , 2003, Brain : a journal of neurology.

[252]  M. M. Soundarapandian,et al.  DAPK1 Interaction with NMDA Receptor NR2B Subunits Mediates Brain Damage in Stroke , 2010, Cell.

[253]  R. Wightman,et al.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.

[254]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[255]  H. Bading,et al.  Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.

[256]  J. Penney,et al.  Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.

[257]  P. Soares-da-Silva,et al.  Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission , 1992, Journal of neurochemistry.

[258]  N. Hardingham,et al.  Nuclear Ca2+ and the cAMP Response Element-Binding Protein Family Mediate a Late Phase of Activity-Dependent Neuroprotection , 2005, The Journal of Neuroscience.

[259]  K. Chu,et al.  Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington’s disease , 2006, Brain Research.

[260]  Carlos Cepeda,et al.  Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. , 2006, Journal of neurophysiology.

[261]  C. Wilson,et al.  Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[262]  K. Roche,et al.  Molecular determinants of NMDA receptor internalization , 2001, Nature Neuroscience.

[263]  D. Bredt,et al.  Synaptic Targeting of the Postsynaptic Density Protein PSD-95 Mediated by Lipid and Protein Motifs , 1999, Neuron.

[264]  H. Bading,et al.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.

[265]  J. Tepper,et al.  GABAA and GABAB antagonists differentially affect the firing pattern of substantia nigra dopaminergic neurons in vivo , 1999, Synapse.

[266]  M. Hayden,et al.  Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.

[267]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[268]  D. Langbehn,et al.  Earliest functional declines in Huntington disease , 2010, Psychiatry Research.

[269]  Ruth Luthi-Carter,et al.  Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation , 2003, Neurobiology of Disease.

[270]  H. Kita,et al.  Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations , 1988, Brain Research.

[271]  A. Strafella,et al.  Bilateral globus pallidus stimulation for Huntington's disease , 2004, Annals of neurology.

[272]  R. Heumann,et al.  Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain , 2004, Neurobiology of Disease.

[273]  H. Johnston,et al.  A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. , 1999, Human molecular genetics.

[274]  M. Beal,et al.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[275]  P. Calabresi,et al.  Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons , 2006, Neurobiology of Disease.

[276]  J. Penney,et al.  Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. , 1999, Brain research. Molecular brain research.

[277]  D. Coulter,et al.  Specific proteolysis of the NR2 subunit at multiple sites by calpain , 2001, Journal of neurochemistry.

[278]  C. Cepeda,et al.  Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function , 2011, ASN neuro.

[279]  D. Choquet,et al.  NMDA receptor surface mobility depends on NR2A-2B subunits , 2006, Proceedings of the National Academy of Sciences.

[280]  M. Chesselet,et al.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.

[281]  R. Albin,et al.  Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues , 1993, Nature Genetics.

[282]  A. Rasmussen,et al.  Huntington disease in children: genotype-phenotype correlation. , 2000, Neuropediatrics.

[283]  A. Weindl,et al.  Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)(15)O-PET. , 1999, Brain : a journal of neurology.

[284]  W. Strittmatter,et al.  In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. , 2003, Archives of biochemistry and biophysics.

[285]  Ann Marie Craig,et al.  NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo , 2007, The Journal of Neuroscience.

[286]  Carlos Cepeda,et al.  Alterations in Cortical Excitation and Inhibition in Genetic Mouse Models of Huntington's Disease , 2009, The Journal of Neuroscience.

[287]  E. Richfield,et al.  Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients , 1995, Annals of neurology.

[288]  S. Augood,et al.  Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease , 2004, Neurobiology of Disease.

[289]  G. Westbrook,et al.  The Incorporation of NMDA Receptors with a Distinct Subunit Composition at Nascent Hippocampal Synapses In Vitro , 1999, The Journal of Neuroscience.

[290]  J. B. Martin,et al.  Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.

[291]  H. Manev,et al.  NMDA-stimulated expression of BDNF mRNA in cultured cerebellar granule neurones. , 1993, Neuroreport.

[292]  M. Chesselet,et al.  Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.

[293]  Scott J Barton,et al.  Altered Information Processing in the Prefrontal Cortex of Huntington's Disease Mouse Models , 2008, The Journal of Neuroscience.